摘要
目的探讨中期因子(midkine,MK)在卵巢上皮肿瘤中的表达及与其临床病理特征的关系。方法采用免疫组织化学法(SP法),检测MK在卵巢良性上皮性肿瘤、交界性肿瘤和上皮性癌组织中的表达水平,同时以正常卵巢上皮组织中MK表达水平作为对照。结果正常卵巢组织中MK无表达,良性卵巢上皮性肿瘤组织中MK阳性表达率为13.3%,交界性上皮肿瘤组织为50.0%,卵巢癌组织为89.1%,差异有显著性(P<0.05),MK表达与肿瘤病理类型无相关性(P>0.05)。Ⅱ～Ⅳ期患者其阳性表达率明显高于Ⅰ期患者(P<0.05),有淋巴结转移者MK阳性表达率显著高于无淋巴结转移者(P<0.05)。结论上皮性卵巢癌组织中MK表达增强,MK可作为1种有价值的肿瘤标志物。
Objective To investigate the relation ship between the expression of midkine and the clinical pathology in epithelial ovarian carcinoma tissues.Methods Expression of midkine in ovarian benign epithelial tumors,borderline epithelial tumors and malignant tumors were detected by immunohistochemistry.Results There was no expression of MK in normal ovarial epithelial tissues;The positive expression rate of MK in ovarian benign epithelial tumors,borderline epithelial tumors and epithelial ovarian carcinoma tissues were 13.3%,50.0% and 89.1%,and the differences were significant（P0.05）.The expression of MK had no correlation with the pathological types（P0.05）,but the patients with Ⅱ~Ⅳ diseases and node metastasis had significantly higher expression of MK than those with stageⅠor N0 diseases（P0.05）.Conclusion MK was over-expressed in human epithelial ovarian carcinoma.MK might be an useful tumor marker.
出处
《实用癌症杂志》
2011年第6期593-595,共3页
The Practical Journal of Cancer
